Availability of polymeric nanoparticles for specific enhanced and targeted drug delivery

Therapeutic Delivery

Volumn 4, Issue 10, 2013, Pages 1261-1278

  Kiriyama, Akiko ^a   Iga, Katsumi ^a   Shibata, Nobuhito ^a  

^a DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84885576235     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.84     Document Type: Review

References (150)

1. Nel A, Xia T, Meng H et al. Nanomaterial toxicity testing in the 21st century: use of a predictive toxicological approach and high-Throughput screening. Acc. Chem. Res. 46(3), 607-621 (2013).
2. Hu CM, Zhang L. Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem. Phamacol. 83(8), 1104-1111 (2012).
3. Waite CL, Roth CM. Nanoscale drug delivery systems for enhanced drug penetration into solid tumors: current progress and opportunities. Crit. Rev. Biomed. Eng. 40(1), 21-41 (2012).
4. Guo X, Xing Y, Zhang X et al. In vivo controlled release and prolonged antitumor effects of 2-methoxyestradiol solid lipid nanoparticles incorporated into a thermosensitive hydrogel. Drug Deliv. 19(4), 188-193 (2012).
5. Gao L, Liu G, Ma J, Wang X, Zhou L, Li X. Drug nanocrystals: in vivo performances. J. Control. Release 160(3), 418-430 (2012).
6. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: i, absolute oral bioavailability of nanocrystaline danazol in beagle dogs. Int. J. Pham. 125(1), 91-97 (1995).
7. Dermissman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water soluble drugs. Eur. J. Pharm. Sci. 11(2), S73-S80 (2000).
8. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J. Control. Release. 161(2), 505-522 (2012).
9. Araújo J, Gonzalez E, Egea AM, Garcia ML, Souto EB. Nanomedicines for ocular NSAIDs: safety on drug delivery. Nanomedicine 5(4), 394-401 (2009).
10. Wang Y, Zhang Y, Du Z, Wu M, Zhang G. Detection of micrometastases in lung cancer with magnetic nanoparticles and quantum dots. Int. J. Nanomedicine 7, 2315-2324 (2012).
11. Zhang Q, Chuang KT. Adsorption of organic pollutants from effluents of a kraft pulp mill on activated carbon and polymer resin. Adv. Environ. Res. 5(3), 251-258 (2001).
12. Couvreur P, Dubernet C, Puisieux F. Controlled drug delivery with nanoparticles: current possibilities and future trends. Eur. J. Pharm. Biopharm. 41(1), 2-13 (1995).
13. Couvreur P, Barratt G, Fattal E, Legrand P, Vauthier C. Nanocapsule technology: a review. Crit. Rev. Ther. Drug Carr. Syst. 19(2), 99-134 (2002).
14. Asua JM, Miniemulsion polymerization. Prog. Polym. Sci. 27(7), 1283-1346 (2002).
15. Wang X, Summers CJ, Wang ZL. Large-scale hexagonal-patterned growth of aligned ZnO nanorods for nano-optoelectronics and nanosensor arrays. Nano Lett. 4(3), 423-426 (2004).
16. Hosokawa M, Nogi K, Naito M, Yokoyama T. In: Nanoparticle technology handbook. Elsevier. Amsterdam, Netherlands, (2007).
17. Brahim S, Narinesingh D, Elie GA. Amperometric determination of cholesterol in serum using a biosensor of cholesterol oxidase contained within a polypyrrole-hydrogel membrane. Anal. Chim. Acta. 448(1-2), 27-36 (2001).
18. Jang JS, Oh JH. Novel crystalline supramolecular assemblies of amorphous polypyrrole nanoparticles through surfactant templating. Chem. Commun. 19, 2200-2201 (2002).
19. Fudouzi H, Xia Y. Photonic papers and inks: color writing with colorless materials. Adv. Mater. 15(11), 892-896 (2003).
20. Bédard MF, De Geest BG, Skirtach AG, Möhwald H, Sukhorukov GB. Polymeric microcapsules with light responsive properties for encapsulation and release. Adv. Colloid Interface Sci. 158(1-2), 2-14 (2010).
21. Kumar S, Gope J, Kumar A, Parashar A, Rauthan CM, Dixit PN. High pressure growth of nanocrystalline silicon films. J. Nanosci. Nanotechnol. 8(8), 4211-4217 (2008).
22. Dubey DK, Tomar V. Role of molecular level interfacial forces in hard biomaterial mechanics: a review. Ann. Biomed. Eng. 38(6), 2040-2055 (2010).
23. Maynard AD, Warheit DB, Philbert MA. The new toxicology of sophisticated materials: nanotoxicology and beyond. Toxicol. Sci. 120(Suppl. 1), S109-S129 (2011).
24. Jarzyna PA, Skajaa T, Gianella A et al. Iron oxide core oil-in-water emulsions as a multifunctional nanoparticle platform for tumor targeting and imaging. Biomaterials 30(36), 6947-6954 (2009).
25. Zhang XD, Wu D, Shen X, Liu PX, Fan FY, Fan SJ. In vivo renal clearance, biodistribution toxicity of gold nanoclusters. Biomaterials 33(18), 4628-4638 (2012).
26. Thomas AM, Kapanen AI, Hare JI et al. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration: formulation design, pharmacokinetics and efficacy. J. Control. Release 150(2), 212-219 (2011).
27. Tamura M, Ichinohe S, Tamura A, Ikeda Y, Nagasakia Y. In vitro and in vivo characteristics of core-shell type nanogel particles: optimization of corecross-linking density and surface poly(ethyleneglycol) density in PEGylated nanogels. Acta. Biomater. 7(9), 3354-3361 (2011).
28. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557-570 (2012).
29. Geckeler KE, Stirn J. Polyreationen-mechanismen, systematik, relevanz. Naturwissenschaften 80(11), 487-500 (1993).
30. Puig JE. Microemulsion polymerization (oil-in-water). In: Polymeric materials encyclopedia (volume 6). Salamone JC (Ed.). CRC Press, FL, USA, 4333-4341 (1996).
31. Muñoz-Espí R, Weiss CK, Landfester K. Inorganic nanoparticles prepared in miniemulsion. Curr. Opin. Colloid Interface Sci. 17(4), 212-224 (2012).
32. Yeole N, Hundiwale D, Jana T. Synthesis of core-shell polystyrene nanoparticles by surfactant free emulsion polymerization using macro-RAFT agent. J. Colloid Interface Sci. 354(2), 506-510 (2011).
33. Karode SK, Kulkarni SS, Suresh AK, Mashelker RA. New insights into kinetics and thermodynamics of interfacial polymerization. Chem. Eng. Sci. 53(15), 2649-2663 (1998).
34. Takakura Y, Hashida M. Macromolecular drug carrier system in cancer chemotherapy: macromolecular prodrugs. Crit. Rev. Oncol. Hematol. 18(3), 207-231 (1995).
35. Kratz F, Beyer U, Schutte MT. Drug-polymer conjugates containing acid-cleavable bonds. Crit. Rev. Ther. Drug Carrier Syst. 16(3), 245-288 (1999).
36. Liu L, Xu K, Wang H et al. Self-Assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nat. Nanotechnol. 4(7), 457-463 (2009).
37. Prasad JR, Kurt EG. Polymer nanoparticles: preparation techniques and size-control parameters. Prog. Polym. Sci. 36(7), 887-913 (2011).
38. Haag R, Kratz F. Polymer therapeutics: concepts and applications. Angewandte Chemie 45(8), 1998-1215 (2006).
39. Michailova V, Berlinova I, Iliev P et al. Nanoparticles formed from PNIPAM-g-PEO copolymers in the presence of indomethacin. Int. J. Pharm. 384(1-2), 154-164 (2010).
40. Zhang J, Chen H, Xu L, Gu Y. The targeted behavior of thermally responsive nanohydrogel evaluated by NIR system in mouse model. J. Control. Release. 131(1), 34-40 (2008).
41. Hoare T, Pelton R. Charge-switching, amphoteric glucose-responsive microgels with physiological swelling activity. Biomacromolecules 9(2), 733-740 (2008).
42. Oh JK, Lee DI, Park JM. Biopolymer-based microgels/nanogels for drug delivery applications. Prog. Polym. Sci. 34(12), 1261-1282 (2009).
43. Serrano-Medina A, Cornejo-Bravo JM, Licea- Claveríe A. Synthesis of pH and temperature sensitive, core-shell nano/microgels, by one pot, soap-free emulsion polymerization. J. Colloid. Interface Sci. 369(1), 82-90 (2012).
44. Gao L, Liu G, Wang X, Liu F, Xu JM. Preparation of a chemically stable quercetin formulation using nanosuspension technology. Int. J. Pharm. 404(1-2), 231-237 (2011).
45. Sarkari M, Brown J, Chen X, Swinnea S, Williams III RO, Johnston KP. Enhanced drug dissolution using evaporative precipitation into aqueous solution. Int. J. Pham. 243(1-2), 17-31 (2002).
46. Guo Z, Pereira T, Choi O, Wang Y, Hahn HT. Surface functionalized alumina nanoparticle filled porimeric nanoparticles with enhanced mechanical properties. J. Mater. Chem. 16(27), 2800-2808 (2006).
47. Gao L, Zhang D, Chen M et al. Studies on pharmaciokinetics and tissue distribution of oridonin nanosuspensions. Int. J. Pharm. 355(1-2), 321-327 (2008).
48. Yang W, Peters JI, Williams III RO. Inhaled nanoparticles: a current view. Int. J. Pham. 356(1-2), 239-247 (2008).
49. Okada H. One- And three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv. Drug Deliv. Rev. 28(1), 3-70 (1997).
50. Matthews PA. Hormone ablation therapy: lightening the load for today's prostate cancer patient. Urol. Nurs. 27(Suppl.), 3-11 (2007).
51. Shahnaza G, Vettera A, Barthelmesa J et al. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization. Int. J. Pharm. 428(1-2), 164-170 (2012).
52. Mizushima Y, Yanagawa A, Hoshi K. Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J. Pharm. Pharmacol. 35(10), 666-667 (1983).
53. Cox JW, Andreadis NA, Bone RC et al. Pulmonary extraction and pharmacokinetics of prostaglandin E1 during continuous intravenous infusion in patients with adult respiratory distress syndrome. Am. Rev. Respir. Dis. 137(1), 5-12 (1988).
54. Cawello W, Schweer H, Dietrich B et al. Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-Term infusion of prostaglandin E1 in patients with erectile dysfunction. J. Urol. 158(4), 1403-1407 (1997).
55. Takenaga M, Ohta Y, Tokura Y, Hamaguchi A, Igarashi R. Comparison study of lipo PGE1 preparations. Yakugaku Zasshi 127(8), 1237-1243 (2007).
56. Komori Y, Aiba T, Kushima M, Kawasaki H, Kurosaki Y. Alteration of therapeutic efficacy of lipid microspheres incorporating prostaglandin E1 by mixing with aqueous solution. J. Pharm. Sci. 96(4), 935-943 (2007).
57. Igarashi R, Takenaga M, Takeuchi J, Kitagawa A, Matsumoto K, Mizushima Y. Marked hypotensive and blood flow-increasing effects of a new lipo-PGE(1) (lipo- AS013) due to vascular wall targeting. J. Control. Release 71(2), 157-164 (2001).
58. Brass EP, Anthony R, Dormandy J et al. Circulase investigators. Parenteral therapy with lipo-ecraprost, a lipid-based formulation of a PGE1 analog, does not alter six-month outcomes in patients with critical leg ischemia. J. Vasc. Surg. 43(4), 752-759 (2006).
59. Takenaga M, Ishihara T, Ohta Y et al. Nano PGE1 promoted the recovery from spinal cord injury-induced motor dysfunction through its accumulation and sustained release. J. Control. Release 148(2), 249-254 (2010).
60. Xie Y, Bagby TR, Cohen MS, Forrest ML. Drug delivery to the lymphatic system: importance in future cancer diagnosis and therapies. Expert Opin. Drug Deliv. 6(8), 785-792 (2009).
61. Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle 6(22), 2782-2787 (2007).
62. Lorusso V, Manzione L, Silvestris N. Role of liposomal anthracyclines in breast cancer. Ann. Oncol. 18(Suppl. 6), vi70-vi73 (2007).
63. Rahman AM, Yusuf SW, Ewer MS. Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation. Int. J. Nanomedicine 2(4), 567-583 (2007).
64. Udhrain A, Skubitz KM, Northfelt DW. PEGylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma. Int. J. Nanomedicine 2(3), 345-352 (2007).
65. Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G. PEGylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol. 18(7), 1159-1164 (2007).
66. Bibbya DC, Talmadgeb JE, Dalala MK et al. Pharmacokinetics and bio-distribution of RGD-Targeted doxorubicin-loaded nanoparticles in tumor-bearing mice. Int. J. Pharm. 293(1-2), 281-290 (2005).
67. Hillery AM. Supramolecular lipidic drug delivery systems: from laboratory to clinic. A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B. Adv. Drug Deliv. Rev. 24(2-3), 345-363 (1997).
68. Lestner JM, Howard SJ, Goodwin J et al. Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 54(8), 3432-3441 (2010).
69. Fukui H, Koike T, Nakagawa T et al. Comparison of LNS-AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®), with commercial lipid-based formulations. Int. J. Pharm. 267(1-2), 101-112 (2003).
70. Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS. Recent advances in the management of mucormycosis: from bench to bedside. Clin. Infect. Dis. 48(12), 1743-1751 (2009).
71. Van de Ven H, Paulussen C, Feijens PB et al. PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome. J. Control. Release 161(3), 795-803 (2012).
72. Nathanson N, Langmuir AD. The Cutter Incident. Poliomyelitis following formaldehyde-inactivated poliovirus vaccination in the United States during the spring of 1955. ii. Relationship of poliomyelitis to cutter vaccine. Am. J. Hyg. 78, 29-60 (1963).
73. Bellet JS, Prose NS. Skin complications of Bacillus Calmette-Guerin immunization. Curr. Opin. Infect. Dis. 18(2), 97-100 (2005).
74. Ingolotti M, Kawalekar O, Shedlock DJ, Muthumani K, Weiner DB. DNA vaccines for targeting bacterial infections. Expert Rev. Vaccines 9(7), 747-763 (2010).
75. Zhao K, Shi X, Zhao Y et al. Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine 29(47), 8549-8556 (2011).
76. Cherif MS, Shuaibu MN, Kurosaki T et al. Immunogenicity of novel nanoparticle-coated MSP-1 C-Terminus malaria DNA vaccine using different routes of administration. Vaccine 29(48), 9038-9050 (2011).
77. Lee HJ, Park N, Cho HJ et al. Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1. Vaccine 28(6), 1613-1619 (2010).
78. Fujita Y, Taguchi H. Current status of multiple antigen-presenting peptide vaccine systems: application of organic and inorganic nanoparticles. Chem. Cent. J. 5(1), 48 (2011).
79. Chen Y-S, Hung Y-C, Lin W-H, Huang GS. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-And-mouth disease virus peptide. Nanotechnology 21(19), 195101 (2010).
80. Cruz LJ, Rueda F, Cordobilla B et al. Targeting nanosystems to human DCs via Fc receptor as an effective strategy to deliver antigen for immunotherapy. Mol. Pharm. 8(1), 104-116 (2011).
81. des Rieux A, Fievez V, Garinot M, Schneider YJ, Préat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116(1), 1-27 (2006).
82. Krishnamachari Y, Geary SM, Lemke CD, Salem AK. Nanoparticle delivery systems in cancer vaccines. Pharm. Res. 28(2), 215-236 (2011).
83. Tan A, de la Peña H, Seifalian AM. The application of exosomes as a nanoscale cancer vaccine. Int. J. Nanomedicine. 5, 889-900 (2010).
84. US Food and Drug Administration. FDA approves a cellular immunotherapy for men with advanced prostate cancer. Mol. Cell Pharmacol. 2(3), 122-123 (2010).
85. Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin. Prostate Cancer 4(1), 55-60 (2005).
86. Rini B, Weinberg V, Fong L, Small E. A Phase II study of prostate acid phosphatase-pulsed dendritic cells (APC8015; Provenge) in combination with bevacizumab in patients with serologic progression of prostate cancer following local therapy. (Proc. Am. Soc. Clin. Oncol. 22) Presented at: 2003 ASCO Annual Meeting. (Abstract No 699), IL, USA, 31 May-3 June 2003.
87. Reddy ST, Berk DA, Jain RK. Swartz MA. A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. J. Appl. Physiol. 101(4), 1162-1169 (2006).
88. Oussoren C, Storm G. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Deliv. Rev. 50(1-2), 143-156 (2001).
89. Nishioka Y, Yoshino H. Lymphatic targeting with nanoparticulate system. Adv. Drug Deliv. Rev. 47(1), 55-64 (2001).
90. Hawley AE, Davis SS, Illum L. Targeting of colloids to lymph nodes: influence of lymphatic physiology and colloidal characteristics. Adv. Drug Deliv. Rev. 17(1), 129-148 (1995).
91. Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid composition and lipid dose. Biochim. Biophys. Acta Biomembranes 1328(2), 261-272 (1997).
92. Senior J. Fate and behaviour of liposomes in vivo: a review morphology of controlling factors. Ther. Drug Carrier Syst. 3(2), 123-193 (1987).
93. Schwartz RS, Tanaka Y, Fidler IJ, Chiu DT, Lubin B, Scroit AJ. Increased adherence of sickled and phosphatidylserine-enriched human erythrocytes to cultured human peripheral blood monocytes. J. Clin. Invest. 75(6), 1965-1972 (1985).
94. Reddy ST, Swartz MA, Hubbell JA. Targeting dendritic cells with biomaterials: developing the next generation of vaccines. Trends Immunol. 27(12), 573-579 (2006).
95. Rehor A, Hubbell JA, Tirelli N. Oxidation-sensitive polymeric nanoparticles. Langmuir 21(1), 411-417 (2005).
96. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release 112(1), 26-34 (2006).
97. O'Hagan D, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines 2(2), 269-283 (2003).
98. Garnett MC, Kallinteri P. Nanomedicines and nanotoxicology: some physiological principles. Occup. Med. 56(5), 307-311 (2006).
99. Kabanov AV. Polymer genomics: an insight into pharmacology and toxicology of nanomedicines. Adv. Drug Deliv. Rev. 58(15), 1597-1621 (2006).
100. Skwarczynski M, Toth I. Peptide-based subunit nanovaccines. Curr. Drug Deliv. 8(3), 282-289 (2011).
101. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert. Rev. Vaccines 9(9), 1095-1107 (2010).
102. Mumper RJ, Cui Z, Oyewumi MO. Nanotemplate engineering of cell specific nanoparticles. J. Disperse. Sci. 24(3), 569-588 (2003).
103. Monfardini C, Veronese M. Stabilization of substances in circulation. Bioconjug. Chem. 9(4), 418-450 (1998).
104. Kim GJ, Nie S. Targeted cancer nanotherapy. Materials Today 8(8 Suppl. 1), 28-33 (2005).
105. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR, Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of stealth liposomes in tumor tissue. Cancer Res. 53(16), 3765-3770 (1993).
106. Fifis T, Gamvrellis A, Crimeen-Irwin B et al. Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173(5), 3148-3154 (2004).
107. Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J. Control. Release. 112(1), 26-34 (2006).
108. Sharp FA, Ruane D, Claass B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci. USA 106(3), 870-875 (2009).
109. Cruz LJ, Tacken PJ, Fokkink R et al. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro. J. Control. Release 144(2), 118-126 (2010).
110. Newman KD, Elamanchili P, Kwon GS, Samuel J. Uptake of poly(d,l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J. Biomed. Mater Res. 60(3), 480-486 (2002).
111. Xiang SD, Scholzen A, Minigo G et al. Pathogen recognition and development of particulate vaccines: does size matter? Methods 40(1), 1-9 (2006).
112. Hallaj-Nezhadi S, Lotfipour F, Dass C. Nanoparticle-mediated interleukin-12 cancer gene therapy. J. Pharm. Pharm. Sci. 13(3), 472-485 (2010).
113. Yockman JW, Maheshwari A, Han SO, Kim SW. Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J. Control. Release 87(1-3), 177-186 (2003).
114. Maheshwari A, Mahato RI, McGregor J et al. Soluble biodegradable polymer-based cytokine gene delivery for cancer treatment. Mol. Ther. 2(2), 121-130 (2000).
115. Mahato RI, Lee M, Han S, Maheshwari A, Kim SW. Intratumoral delivery of p2CMVmIL-12 using water-soluble lipopolymers. Mol. Ther. 4(2), 130-138 (2001).
116. Fewell JG, Matar M, Slobodkin G et al. Synthesis and application of a nonviral gene delivery system for immunogene therapy of cancer. J. Control Release 109(1-3), 288-298 (2005).
117. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Codelivery of drugs and DNA from cationic core-shell nanoparticles self-Assembled from a biodegradable copolymer. Nat. Mater 5(10), 791-796 (2006).
118. Rodrigo-Garzon M, Berraondo P, Ochoa L, Zulueta JJ, Gonzalez-Aseguinolaza G. Antitumoral efficacy of DNA nanoparticles in murine models of lung cancer and pulmonary metastasis. Cancer Gene Ther. 17(1), 20-27 (2010).
119. Fewell JG, Matar MM, Rice JS et al. Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally. J. Gene Med. 11(8), 718-728 (2009).
120. Niu L, Xu YC, Xie HY, Dai Z, Tang HQ. Expression of human insulin gene wrapped with chitosan nanoparticles in NIH3T3 cells and diabetic rats. Acta. Pharmacol. Sin. 29(11), 1342-1349 (2008).
121. Niu L, Xu YC, Dai Z, Tang HQ. Gene therapy for Type 1 diabetes mellitus in rats by gastrointestinal administration of chitosan nanoparticles containing human insulin gene. World J. Gastroenterol. 14(26), 4209-4215 (2008).
122. Opitz AW, Wickstrom E, Thakur ML, Wagner NJ. Physiologically based pharmacokinetics of molecular imaging nanoparticles for mRNA detection determined in tumor-bearing mice. Oligonucleotides 20(3), 117-125 (2010).
123. Tian X, Aruva MR, Qin W et al. External imaging of CCND1 cancer gene activity in experimental human breast cancer xenografts with 99mTc-peptide-peptide nucleic acid-peptide chimeras. J. Nucl. Med. 45(12), 2070-2082 (2004).
124. Maeda-Mamiya R, Noiri E, Isobe H et al. In vivo gene delivery by cationic tetraamino fullerene. Proc. Natl Acad. Sci. USA 107(12), 5339-5344 (2010).
125. Liu J, Guo S, Cinier M et al. Fabrication of stable and RNase-resistant RNA nanoparticles active in gearing the nanomotors for viral DNA packaging. ACS Nano 5(1), 237-246 (2011).
126. Shu D, Shu Y, Haque F, Abdelmawla S, Guo P. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat. Nanotechnol. 6(10), 658-667 (2011).
127. Abdelmawla S, Guo S, Zhang L et al. Pharmacological characterization of chemically synthesized monomeric pRNA nanoparticles for systemic delivery. Mol. Ther. 19(7), 1312-1322 (2011).
128. Lee JB, Hong J, Bonner DK, Poon Z, Hammond PT. Self-Assembled RNA interference microsponges for efficient siRNA delivery. Nat. Mater. 11(4), 316-322 (2012).
129. Guo P. The emerging field of RNA nanotechnology. Nat. Nanotechnol. 5(12), 833-842 (2010).
130. Salas M. A passion for research. Cell Mol. Life Sci. 66(24), 3827-3830 (2009).
131. Kataoka K, Itaka K, Nishiyama N, Yamasaki Y, Oishi M, Nagasaki Y. Smart polymeric micelles as nanocarriers for oligonucleotides and siRNA delivery. Nucleic Acids Symp. Ser. 49, 17-18 (2009).
132. Hirakura T, Yasugi K, Nemoto T et al. Hybrid hyaluronan hydrogel encapsulating nanogel as a protein nanocarrier: new system for sustained delivery of protein with a chaperone-like function. J. Control. Release 142(3), 483-489 (2010).
133. Wu W, Mitra N, Yan EC, Zhou S. Multifunctional hybrid nanogel for integration of optical glucose sensing and self-regulated insulin release at physiological pH. ACS Nano 4(8), 4831-4839 (2010).
134. Carvalhoa V, Castanheirab P, Fariac TQ et al. Biological activity of heterologous murine interleukin-10 and preliminary studies on the use of a dextrin nanogel as a delivery system. Int. J. Pharm. 400(1-2), 234-242 (2010).
135. Shah PP, Desai PR, Patel AR, Singh MS. Skin permeating nanogel for the cutaneous co-delivery of two anti-inflammatory drugs. Biomaterials 33(5), 1607-1617 (2012).
136. Bhattacharyya S, Guillot S, Dabboue H, Tranchant JF, Salvetat JP. Carbon nanotubes as structural nanofibers for hyaluronic acid hydrogel scaffolds. Biomacromolecules 9(2), 505-509 (2008).
137. Rodrigues LAS, Figueiras A, Veiga F et al. The systems containing clays and clay minerals from modified drug release: a review. Colloids Surf. B Biointerfaces 103, 642-651(2013).
138. Wu W, Shen J, Banerjee P, Zhou S. Core-shell hybrid nanogels for integration of optical temperature-sensing, targeted tumor cell imaging, and combined chemo-photothermal treatment. Biomaterials 31(29), 7555-7566 (2010).
139. Koutsopoulos S, Unsworth LD, Nagai Y, Zhang S. Controlled release of functional proteins through designer self-Assembling peptide nanofiber hydrogel scaffold. Proc. Natl Acad. Sci. USA. 24, 4623-4628 (2009).
140. Hou Q, DeBank PA, Shakeshef KM. Injectable scaffolds for tissue regeneration. J. Mater. Chem. 14(13), 1915-1923 (2004).
141. Elisseeff J. Injectable cartilage tissue engineering. Expert Opin. Biol. Theor. 4(12), 1849-1859 (2004).
142. Nagai Y, Unsworth LD, Koutsopoulos S, Zhang S. Slow release of molecules in self-Assembling peptide nanofiber scaffold. J. Control. Release 115(1), 18-25 (2006).
143. Nishimura A, Hayakawa T, Yamamoto Y et al. Controlled release of insulin from self-Assembling nanofiber hydrogel, PuraMatrixTM: application for the subcutaneous injection in rats. Eur. J. Pharm. Sci. 45(1-2), 1-7 (2012).
144. Singka GSL, Samaha NA, Zulfakar MH, Yurdasiper A, Heard CM. Enhanced topical delivery and anti-inflammatory activity of methotrexate from an activated nanogel. Eur. J. Pharmaceu. Biopharmaceu. 76, 275-281 (2010).
145. Samah NA, Williams N, Heard CM. Nanogel particulates located within diffusion cell receptor phases following topical application demonstrates uptake into and migration across skin. Int. J. Pharm. 401(1-2), 72-78 (2010).
146. Carvalho V, Castanheira P, Madureira P et al. Self-Assembled dextrin nanogel as protein carrier: controlled release and biological activity of IL-10. Biotechnol. Bioeng. 108(8), 1977-1986 (2011).
147. Wu W, Shen J, Banerjee P, Zhou S. Chitosan-based responsive hybrid nanogels for integration of optical pH-sensing, tumor cell imaging and controlled drug delivery. Biomaterials 31(32), 8371-8381 (2010).
148. Dong Y, Saeed AO, Hassan W et al. One-step preparation of thiol-ene clickable PEG-based thermoresponsive hyperbranched copolymer for in situ crosslinking hybrid hydrogel. Macromol. Rapid Commun. 33, 120-126 (2012).
149. Lvov Y, Abdullayev E. Functional polymer-clay nanotube composites with sustained release of chemical agents. Prog. Polym. Sci. 38, 1690-1719 (2013).
150. Taghizadeh MT, Sabouri N. Study of enzymatic degradation and water absorption of nanocomposites polyvinyl alchol/starch/ carboxymethyl cellulose blends containing sodium montmorillonite clay nanoparticle by cellulose and a-Amylase. J. Taiwan Inst. Chem. Eng. doi:10.1016/j.jtice.2013.03.012 (2013) (Epub ahead of print).